

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

NCI-H28

RRID:CVCL_1555

Type: Cell Line

Proper Citation

RRID:CVCL_1555

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1555

Proper Citation: RRID:CVCL_1555

Description: Cell line NCI-H28 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pleural malignant mesothelioma

Defining Citation: [PMID:1568228](#), [PMID:6272398](#), [PMID:8183553](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:11070089](#), [PMID:11464291](#), [PMID:16630136](#), [PMID:17270034](#), [PMID:20164919](#), [PMID:21245096](#), [PMID:21642991](#), [PMID:22460905](#), [PMID:23830731](#), [PMID:24926545](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25902174](#), [PMID:26011428](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28553954](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:32586373](#), [PMID:35839778](#)

Comments: Caution: It is not clear if this cell line originate from an epithelioid or sarcomatoid mesothelioma as there are contradictory reports concerning its exact nature., Caution: According to ATCC the ethnicity of the donor is White, but exome analysis finds it to be mostly of African lineage., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H28

Synonyms: H28, H-28, NCIH28, HUT-28, HUT 28, HuT 28, HUT28, Hut28, HuT28

Cross References: CLO:CLO_0008079, EFO:EFO_0006686, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5820, BioSample:SAMN03471010, BioSample:SAMN10987612, BioSamples:SAMEA100874, cancercellines:CVCL_1555, Cell_Model_Passport:SIDM00720, ChEMBL-Cells:ChEMBL3308775, ChEMBL-Targets:ChEMBL1075541, Cosmic:688059, Cosmic:733814, Cosmic:877108, Cosmic:877350, Cosmic:886387, Cosmic:908470, Cosmic:980995, Cosmic:1032386, Cosmic:1146909, Cosmic:1152495, Cosmic:1481543, Cosmic:1522766, Cosmic:1541208, Cosmic:1749556, Cosmic:1963325, Cosmic:1995572, Cosmic:2474149, Cosmic:2758840, Cosmic:2758998, Cosmic:2759230, Cosmic-CLP:908470, DepMap:ACH-000648, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10845-111E8, GDSC:908470, GEO:GSM171870, GEO:GSM171871, GEO:GSM434272, GEO:GSM726267, GEO:GSM794268, GEO:GSM850284, GEO:GSM887425, GEO:GSM888504, GEO:GSM1670236, GEO:GSM1887939, GEO:GSM1887973, IARC_TP53:21567, IARC_TP53:23623, IGRhCellID:H28GEO, KCLB:90028, LiGeA:CCLE_571, PharmacDB:NCIH28_1099_2019, PRIDE:PXD030304, Progenetix:CVCL_1555, PubChem_Cell_line:CVCL_1555, Wikidata:Q54908002

ID: CVCL_1555

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181245+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H28.

Warning: Discontinued: KCLB; 90028

Caution: It is not clear if this cell line originate from an epithelioid or sarcomatoid mesothelioma as there are contradictory reports concerning its exact nature., Caution: According to ATCC the ethnicity of the donor is White, but exome analysis finds it to be mostly of African lineage., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Graham RN, et al. (2026) A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer. *Cytotherapy*, 28(6), 102101.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Zhong C, et al. (2025) Deoxypodophyllotoxin inhibited the growth of malignant pleural mesothelioma by inducing necroptosis and mitotic catastrophe. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 143, 156786.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Carpentier J, et al. (2025) Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma. *iScience*, 28(1), 111525.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Hirai S, et al. (2024) Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. *Molecular cancer therapeutics*, 23(2), 212.

Hagiyama M, et al. (2024) Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1. *Journal of controlled release : official journal of the Controlled Release Society*, 371, 603.

Chen H, et al. (2024) Targeted degradation of specific TEAD paralogs by small molecule degraders. *Heliyon*, 10(18), e37829.

Hillen H, et al. (2024) A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models. *Molecular cancer therapeutics*, 23(1), 3.

Pandey GK, et al. (2023) Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. *Cell reports. Medicine*, 4(2), 100915.

Maille E, et al. (2022) A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial. *International journal of cancer*, 150(11), 1889.

Lappin KM, et al. (2022) Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. *Cancer research*, 82(5), 819.

Gonzalez VD, et al. (2021) High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. *Cell reports*, 36(9), 109632.

Oehl K, et al. (2021) Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(8), 2277.

Bernard M, et al. (2021) Optimization of Advanced Live-Cell Imaging through Red/Near-Infrared Dye Labeling and Fluorescence Lifetime-Based Strategies. *International journal of molecular sciences*, 22(20).

Yang H, et al. (2021) NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. *Cancers*, 13(7).

Yang H, et al. (2020) Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. *Cancers*, 12(8).

Xu D, et al. (2019) Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. *Cancers*, 11(10).

Kolluri KK, et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. *eLife*, 7.